As the tumor microenvironment is a complex system, the selection of patients suitable for PD-1/PD-L1 blockade should be conducted on the basis of a broad range of predictive markers that can include sensitivity to both IFN-γ and type I IFN signaling. The gene discussed is IFNG; the disease is neoplasm.